Levomefolate.

Methionine synthase hands the methyl group from 5-methyltetrahydrofolate to cobalamin and then to homocysteine. Without enough B12 the folate pool stays stuck in its methyl form and cannot re-enter the cycle.

Methylcobalamin is the cofactor form that accepts the methyl group carried by levomefolate. Pairing the two active forms keeps the remethylation step supplied on both sides.

MTHFR, the enzyme that makes 5-methyltetrahydrofolate, carries an FAD cofactor derived from riboflavin. Riboflavin status shapes how much active folate the body can generate itself.

Levomefolate feeds the remethylation route while pyridoxal-5-phosphate runs the transsulfuration route through cystathionine beta-synthase. The two routes divide the same homocysteine pool between them.

Betaine remethylates homocysteine through BHMT without using folate. It covers the same step when folate-dependent remethylation is running slowly.

Choline is oxidised to betaine and becomes a methyl donor, so choline and folate intake substitute for each other. Low intake of one raises demand on the other.

Serine hydroxymethyltransferase moves a one-carbon unit from serine onto tetrahydrofolate, which is where most of the folate-borne methyl groups originate. Serine supply sets the loading rate of the folate pool.

The glycine cleavage system transfers a carbon unit to tetrahydrofolate, a second entry point into the same pool. Glycine and serine interconvert, so both sit upstream of methylfolate.

Methyl groups delivered by levomefolate end up in methionine and then SAM-e, the universal methyl donor. SAM-e also feeds back on MTHFR, so the two sit at opposite ends of one loop.

Folinic acid enters the folate pool upstream of the MTHFR step and can be converted onward, while levomefolate enters at the methyl end. Together they cover both sides of the folate cycle.

Intestinal folate conjugase and methionine synthase reductase depend on zinc. Low zinc status slows how dietary polyglutamate folate is released and how the methylation cycle is maintained.

Folic acid and levomefolate cross the intestinal wall through the same proton-coupled folate transporter and reduced folate carrier, so they compete for the same route when given together. Folic acid additionally requires two reduction steps by dihydrofolate reductase before it becomes usable, while levomefolate is already at the circulating oxidation state. High folic acid intake also raises unmetabolised folic acid in plasma, a marker rather than an outcome. Combining both in one formula makes the delivered folate picture harder to read.

Reduced folates including 5-methyltetrahydrofolate oxidise readily in air and in solution, which is the main stability problem in formulating them. Ascorbate is the conventional antioxidant used to protect reduced folate in liquids and in the gut lumen. The role is chemical protection, not a change in transport or metabolism. This is settled formulation chemistry.

Red blood cell production needs both folate for DNA synthesis in dividing precursors and iron for haemoglobin, which is why the two are combined in prenatal and blood-support formulas. They act at different steps and neither substitutes for the other. Iron salts are oxidising and can degrade reduced folate in a shared matrix, so formulators separate or protect them. Read the pairing as complementary roles in one process.

Methionine synthase transfers the methyl group from 5-methyltetrahydrofolate to homocysteine to regenerate methionine, which is then activated to S-adenosylmethionine. Supplying methionine loads the same cycle from the product end rather than the donor end. High methionine intake without adequate folate, B12 and B6 raises circulating homocysteine, a marker. The two sit on opposite sides of one reaction, which is why they are discussed together.

Homocysteine has two fates: remethylation to methionine, which 5-methyltetrahydrofolate drives, and transsulfuration to cysteine and onward to glutathione. NAC supplies cysteine directly and reduces the pull on the transsulfuration branch. The two therefore address the same intermediate from different directions. Homocysteine is a biochemical marker, not an outcome in itself.

Myo-inositol is combined with active folate in preconception and reproductive-support products, where each has its own established role. Inositol works in phosphoinositide signalling and insulin signal transduction, unrelated to one-carbon transfer. The pairing stacks two independent inputs in one formula. It is category practice rather than a demonstrated interaction.

Methylenetetrahydrofolate reductase, the enzyme that produces 5-methyltetrahydrofolate in the body, uses NADPH as its reducing cofactor, and NADPH derives from niacin-based nucleotides. Dihydrofolate reductase is NADPH-dependent too. Supplying the finished 5-MTHF bypasses the MTHFR step, so the dependency matters more for the endogenous route than for the supplemented one. This is textbook cofactor biochemistry.

EGCG inhibits dihydrofolate reductase in cell-free and cell-culture systems, which is the step that converts folic acid toward usable reduced folate. Levomefolate does not need that step, so the interaction is more relevant to folic acid than to the active form. The finding is in vitro and its size in people at dietary catechin intakes is not established. Read it as mechanistic.

Magnesium is a required cofactor for the ATP-dependent activation of methionine to S-adenosylmethionine and for many downstream methyltransferases. That places it in the same cycle that 5-methyltetrahydrofolate feeds. Deficiency of magnesium is not the usual bottleneck in that cycle, so the relationship is supportive rather than rate-setting. This is standard biochemistry.

The most widely used commercial form of levomefolate is its calcium salt, so calcium is present as the counterion by design rather than as an added partner. The salt improves crystallinity and handling of an otherwise unstable reduced folate. Calcium from other sources in the same formula does not add to that role. The relationship is formulation chemistry.

Cysteine is the product of the transsulfuration branch that consumes homocysteine, the same intermediate the folate-dependent remethylation branch handles. Adequate cysteine reduces demand on that branch and supports glutathione synthesis. The two therefore sit on the same node of one-carbon and sulfur metabolism. Homocysteine remains a marker rather than a clinical outcome.

Thiamine appears with active folate in B-complex formulas and has its own role as thiamine pyrophosphate in decarboxylation reactions. It has no direct step in the folate cycle. The pairing reflects the B-complex convention rather than a shared reaction. Regard it as formulation practice.